TNF and cancer: Many other cells, including T cells and monocytes, could also be engineered to target delivery of TNFα to cancer cells in combination with an IAP antagonist because an IAP antagonist enables TNFα to rapidly induce apoptosis in a broad range of cancers [52–54].